WHO ICTRP trial
Safety and efficacy of glinide for the treatment of type 2 diabetic patients
JPRN-UMIN000003840 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000003840 |
|---|---|
| Public title | Safety and efficacy of glinide for the treatment of type 2 diabetic patients |
| Scientific title | Safety and efficacy of glinide for the treatment of type 2 diabetic patients - Safety and efficacy of glinide for the treatment of type 2 diabetic patients |
| Primary sponsor | Keio University School of Medicine Department of Medicine Division of Nephrology, Endocrinology and Metabolism |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase IV |
| Countries | Japan |
| Conditions | type 2 diabetes |
| Interventions | Mitiglinide 10mg three times daily will be added for 4 months. If the glycemic control are suboptimal (HbA1c(JDS) 6.5% or more) 2 month after the treatment, the patients will be treated with mitiglinide 20mg three times daily. |
| Registration date | Jan 7, 2010 |
| Target size | 30 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: